Abstract:BACKGROUND: Clear cell renal cell carcinoma (ccRCC) is the most lethal renal cancer. An overwhelming increase of patients experience tumor progression and unfavorable prognosis. However, the molecular events underlying ccRCC tumorigenesis and metastasis remain unclear. Therefore, uncovering the underlying mechanisms will pave the way for developing novel therapeutic targets for ccRCC. In this study, we sought to investigate the role of mitofusin-2 (MFN2) in supressing ccRCC tumorigenesis and metastasis.METHODS: The expression pattern and clinical significance of MFN2 in ccRCC were analyzed by using the Cancer Genome Atlas datasets and samples from our independent ccRCC cohort. Both in vitro and in vivo experiments, including cell proliferation, xenograft mouse models and transgenic mouse model, were used to determine the role of MFN2 in regulating the malignant behaviors of ccRCC. RNA-sequencing, mass spectrum analysis, co-immunoprecipitation, bio-layer interferometry and immunofluorescence were employed to elucidate the molecular mechanisms for the tumor-supressing role of MFN2.RESULTS: we reported a tumor-suppressing pathway in ccRCC, characterized by mitochondria-dependent inactivation of epidermal growth factor receptor (EGFR) signaling. This process was mediated by the outer mitochondrial membrane (OMM) protein MFN2. MFN2 was down-regulated in ccRCC and associated with favorable prognosis of ccRCC patients. in vivo and in vitro assays demonstrated that MFN2 inhibited ccRCC tumor growth and metastasis by suppressing the EGFR signaling pathway. In a kidney-specific knockout mouse model, loss of MFN2 led to EGFR pathway activation and malignant lesions in kidney. Mechanistically, MFN2 preferably binded small GTPase Rab21 in its GTP-loading form, which was colocalized with endocytosed EGFR in ccRCC cells. Through this EGFR-Rab21-MFN2 interaction, endocytosed EGFR was docked to mitochondria and subsequently dephosphorylated by the OMM-residing tyrosine-protein phosphatase receptor type J (PTPRJ).CONCLUSIONS: Our findings uncover an important non-canonical mitochondria-dependent pathway regulating EGFR signaling by the Rab21-MFN2-PTPRJ axis, which contributes to the development of novel therapeutic strategies for ccRCC.

Clinical Significance of Mitofusin-2 and Its Signaling Pathways in Hepatocellular Carcinoma

Mitofusin-2 Triggers Mitochondria Ca2+ Influx from the Endoplasmic Reticulum to Induce Apoptosis in Hepatocellular Carcinoma Cells.

Pro-apoptotic and anti-proliferative effects of mitofusin-2 via Bax signaling in hepatocellular carcinoma cells

The mitochondrial fusion-associated protein MFN2 can be used as a novel prognostic molecule for clear cell renal cell carcinoma

Mitochondrial Dysfunction-Related Genes in Hepatocellular Carcinoma

Silencing MFN2 Drives WNT/β-catenin Nucleation to Reduce Sorafenib Sensitivity in Hepatocellular Carcinoma Cells

MFN2 Suppresses Cancer Progression Through Inhibition of Mtorc2/akt Signaling.

MFN2 suppresses the accumulation of lipid droplets and the progression of clear cell renal cell carcinoma

MFN2 suppresses clear cell renal cell carcinoma progression by modulating mitochondria‐dependent dephosphorylation of EGFR

MFN1-dependent Alteration of Mitochondrial Dynamics Drives Hepatocellular Carcinoma Metastasis by Glucose Metabolic Reprogramming

FUNDC2 Promotes Liver Tumorigenesis by Inhibiting MFN1-mediated Mitochondrial Fusion

Mitofusin2 Induces Cell Autophagy of Pancreatic Cancer through Inhibiting the PI3K/Akt/mTOR Signaling Pathway

MTFR2-dependent mitochondrial fission promotes HCC progression

Myocyte Enhancer Factor 2D Promotes Hepatocellular Carcinoma Through AMOTL2/YAP Signaling That Inhibited by Luteolin.

Hepatitis B Virus X Protein Inhibits P53-Mediated Upregulation of Mitofusin-2 in Hepatocellular Carcinoma Cells

Myocyte enhancer factor 2C regulation of hepatocellular carcinoma via vascular endothelial growth factor and Wnt/β-catenin signaling

Mitochondria-ER contact mediated by MFN2-SERCA2 interaction supports CD8 + T cell metabolic fitness and function in tumors

MTFR2 shapes a barrier of immune microenvironment in hepatocellular carcinoma

Mitofusin-2: A New Mediator of Pathological Cell Proliferation

FCN2 Inhibits Epithelial–mesenchymal Transition-Induced Metastasis of Hepatocellular Carcinoma Via TGF-β/Smad Signaling

A novel mitochondrial amidoxime reducing component 2 is a favorable indicator of cancer and suppresses the progression of hepatocellular carcinoma by regulating the expression of p27